[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al
On July 3, 2024, a concerning study published by researchers from Mass Eye and Ear found that patients taking semaglutide, the active ingredient in drugs like Ozempic and Wegovy, may be at a higher risk of developing a rare blinding condition known as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Mechanism of Action When SLU-PP-332 binds to ERR, it activates transcriptional programs normally triggered by endurance exercise, including: Upregulation of PGC-1, the master regulator of mitochondrial gene expression Increased mitochondrial density and oxidative enzyme activity in skeletal and cardiac muscle Enhanced fatty acid oxidation and energy expenditure Improved substrate utilization, as indicated by reduced respiratory exchange ratio (RER) in animal studies
Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al
